Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the clinical safety and feasibility of T-DM1 after the completion of doxorubicin/cyclophosphamide (AC) or 5-fluorouracil (5-FU)/epirubicin/ cyclophosphamide (FEC) adjuvant/neoadjuvant chemotherapy regimen in HER-2/neu overexpressed/amplified early breast cancer (EBC) patients: • To evaluate the rate of cardiac events during T-DM1 treatment when initiated after completion of anthracycline-containing chemotherapy • To evaluate the safety profile of T-DM1
Inclusion criteria
- Treatment of HER2 positive adjuvant or neoadjuvant therapy